Welcome to our dedicated page for Iridex SEC filings (Ticker: IRIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Iridex Corporation (IRIX) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. As a Nasdaq Capital Market issuer incorporated in Delaware with principal offices in Mountain View, California, Iridex uses SEC reports to present information on its ophthalmic laser business, financial condition, and material events.
Key documents for IRIX include Form 10‑K annual reports, which describe the company’s business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for glaucoma, diabetic macular edema (DME), and other retinal diseases. Form 10‑Q quarterly reports provide interim updates on revenues from consoles, delivery devices, consumables, services, and support activities, along with segment information for its ophthalmology operations.
Iridex also files Form 8‑K current reports to announce specific events. Recent 8‑Ks have covered preliminary financial results, quarterly earnings releases, participation in investor conferences, and Nasdaq listing compliance matters, including the company’s notification of non‑compliance with Listing Rule 5550(b) and subsequent confirmation that it regained compliance with the stockholders’ equity requirement.
Investors can further review registration statements, proxy materials, and insider transaction reports such as Form 4, where applicable, to understand equity ownership and governance. On Stock Titan, AI-powered tools summarize lengthy filings, highlight key sections, and help explain complex topics such as non‑GAAP adjusted EBITDA reconciliations, stockholders’ equity, and risk factor disclosures, allowing users to navigate Iridex’s regulatory history more efficiently.
IRIDEX Corporation’s Chief Financial Officer, Romeo R. Dizon, reported an open-market purchase of company stock. On 01/27/2026, he bought 3,385 shares of Common Stock at a price of $1.4799 per share, as shown by transaction code "P" for a purchase. Following this transaction, he beneficially owns 110,289 shares of IRIDEX Common Stock in direct ownership.
IRIDEX Corp Chief Financial Officer buys additional shares. On 01/26/2026, CFO Romeo R. Dizon purchased 1,243 shares of IRIDEX common stock at $1.52 per share in an open-market transaction coded "P" (purchase). After this trade, he directly owned 106,904 shares of IRIDEX common stock. This filing reflects a change in his personal share ownership and does not describe any change in the company’s operations or financial results.
IRIDEX Corporation’s Chief Financial Officer, Romeo R. Dizon, purchased additional shares of the company’s common stock. On 01/23/2026, he bought 5,221 shares at a weighted average price of $1.4779 per share, with individual trade prices ranging from $1.475 to $1.48. Following this purchase, he beneficially owns 105,661 shares of IRIDEX common stock in direct ownership. The transaction was reported as an open-market or private purchase, with full trade-level pricing details available upon request from the company, its security holders, or the SEC staff.
IRIDEX CORP Chief Financial Officer Romeo R. Dizon reported open-market purchases of the company’s common stock. On January 20, 2026, he bought 2,100 shares at a price of $1.4987 per share. On January 21, 2026, he made two additional purchases of 409 shares at $1.53 per share and 1,750 shares at $1.49 per share.
After these transactions, Dizon directly owned 100,440 shares of IRIDEX common stock. The filing indicates these holdings are reported as directly owned, with no indirect ownership relationships noted.
Iridex Corp’s chief financial officer, Romeo R. Dizon, reported multiple acquisitions of the company’s common stock. On January 16, 2026, he acquired several small lots of shares at prices ranging from $1.38 to $1.45 per share, each coded as an acquisition transaction.
After these trades, his directly held beneficial ownership in Iridex common stock was reported at 96,181 shares. All reported holdings are shown as directly owned in his name.
IRIDEX Corporation reported that it has released preliminary, unaudited results for its fourth fiscal quarter and full fiscal year ended January 3, 2026. The company shared these operational and financial figures in a press release dated January 12, 2026, which is attached as Exhibit 99.1. The disclosure is being furnished rather than filed, meaning it is not automatically incorporated into other securities law filings unless specifically referenced.
IRIDEX Corporation reported an insider share issuance involving a major holder. On 01/02/2026, Novel Inspiration International Co., Ltd., a 10% owner, received 116,540 shares of IRIDEX common stock at a stated price of $0 per share as reflected in the Form 4.
The filing explains that these shares were issued as a quarterly interest payment on a Convertible Promissory Note dated March 19, 2025 between IRIDEX and Novel Inspiration. After this transaction, Novel Inspiration is shown as beneficially owning 351,483 shares of IRIDEX common stock. The Form 4 is filed jointly by Novel Inspiration and Shih‑Yao David Lin, who is the sole officer, director and stockholder of Novel Inspiration, while the shares are owned directly by Novel Inspiration.
IRIDEX CORP’s 10% owner Novel Inspiration International Co., Ltd. reported receiving additional common shares. On 10/01/2025, Novel Inspiration acquired 97,610 shares of IRIDEX common stock at a reported price of $0.0000 per share, increasing its beneficial ownership to 234,943 shares held directly.
The shares were issued as a quarterly interest payment on a Convertible Promissory Note that IRIDEX had issued to Novel Inspiration on March 19, 2025. The Form 4 is filed jointly by Novel Inspiration and Shih-Yao David Lin, who is the sole officer, director and stockholder of Novel Inspiration, while the shares themselves are owned directly by Novel Inspiration.
IRIDEX Corp reported an insider ownership change involving a major shareholder. On July 1, 2025, Novel Inspiration International Co., Ltd., identified as a 10% owner of IRIDEX (IRIX), was issued 137,333 shares of common stock.
The Form 4 states that these shares were issued as a quarterly interest payment on a Convertible Promissory Note dated March 19, 2025 between IRIDEX and Novel Inspiration. The shares were received at a stated price of $0.00 per share, and the filing shows 137,333 shares beneficially owned following the transaction, held directly by Novel Inspiration.
The report is filed jointly by Novel Inspiration and Shih-Yao David Lin, who is described as the sole officer, director and stockholder of Novel Inspiration, linking his interests to this 10% ownership position.
IRIDEX Corp reported that Novel Inspiration International Co., Ltd. and Shih‑Yao David Lin are 10% owners via preferred stock and a convertible note. As of March 19, 2025, Novel Inspiration held 600,000 shares of Series B Preferred Stock and a convertible promissory note convertible into 400,000 additional Series B Preferred shares, all owned directly by Novel Inspiration.
Each Series B Preferred share is convertible, at Novel Inspiration’s option, into five shares of common stock with no expiration date, representing 3,000,000 common shares from the existing preferred and a further 2,000,000 common shares from the note. Before required stockholder approval, Novel Inspiration could convert only into 3,356,126 common shares, equal to 19.99% of IRIDEX’s outstanding common stock as of March 19, 2025, and that approval was obtained on June 11, 2025.